
Xiao-Dong Jiao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7019754/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cetuximab and vemurafenib plus FOLFIRIÂ(5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial. European Journal of Cancer, 2022, 163, 152-162.	2.8	7
2	Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. Oncolmmunology, 2021, 10, 1929727.	4.6	32
3	Primary squamous cell carcinoma of pancreas: a population-based study. Gland Surgery, 2021, 10, 1029-1037.	1.1	4
4	Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report. JCO Precision Oncology, 2021, 5, 771-778.	3.0	8
5	<scp> <i>HER2</i> </scp> Splice Site Mutation c. <scp>1899-1G</scp> >A as the Potential Acquired Resistance to Trastuzumab in a Patient with <scp>HER2-Positive</scp> Gastric Adenocarcinoma. Oncologist, 2021, 26, 717-721.	3.7	3
6	Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 3236-3250.	2.8	4
7	Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types. Annals of Translational Medicine, 2020, 8, 860-860.	1.7	9
8	<p>Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget's Disease Harboring Triple Uncommon HER2 Mutation: A Case Report</p> . OncoTargets and Therapy, 2020, Volume 13, 6289-6293.	2.0	7
9	The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer. Critical Reviews in Oncology/Hematology, 2020, 147, 102893.	4.4	33
10	<p>MTSS1 inhibits metastatic potential and induces G2/M phase cell cycle arrest in gastric cancer</p> . OncoTargets and Therapy, 2019, Volume 12, 5143-5152.	2.0	11
11	ldentification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib. Journal of Thoracic Oncology, 2019, 14, e115-e117.	1.1	15
12	Basket Trials for Intractable Cancer. Frontiers in Oncology, 2019, 9, 229.	2.8	22
13	The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. Journal of Thoracic Disease, 2019, 11, 4507-4515.	1.4	27
14	Palbociclib for the Treatment of Metastatic Nasopharyngeal Carcinoma With CDK4 Amplification: A Case Report. JCO Precision Oncology, 2019, 3, 1-4.	3.0	2
15	Primary pulmonary leiomyosarcoma: A population-based study. Lung Cancer, 2018, 116, 67-72.	2.0	28
16	Clinical, pathological and treatment factors associated with the survival of patients with primary pulmonary salivary gland-type tumors. Lung Cancer, 2018, 126, 174-181.	2.0	28
17	Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy. Medical Hypotheses, 2018, 116, 111-113.	1.5	19
18	The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. OncoTargets and Therapy, 2018, Volume 11, 4739-4745.	2.0	23

#	Article	IF	CITATIONS
19	Adenosquamous carcinoma of the bile duct: a population-based study. Cancer Management and Research, 2018, Volume 10, 439-446.	1.9	15